U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

Novo Nordisk, the maker of Ozempic and Wegovy, has also jumped into the legal fight —this time by intervening in the OFA’s lawsuit against the FDA. The company supports the agency’s move to restrict ...

The FDA has said it has agreed to reconsider its decision to prevent compounding pharmacies from producing and selling versions of Eli ... sold by Lilly as Mounjaro for diabetes and Zepbound ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Eli Lilly shares are now positive for the year, up 10% since the start of January.

That’s the hope,” Skovronsky said. To put that in perspective, the highest dose of Zepbound, Eli Lilly’s injectable GLP-1 drug approved for obesity management, leads to an almost 15% weight ...

Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of ...

Zepbound, which has the same active ingredient, tirzepatide, is the brand name for the U.S. weight loss version, with Mounjaro sold for diabetes there. Lilly offers 5 mg, 7.5 mg and 10 mg vials of ...

Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...